Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
March 3, 2026
Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases
PG
Princy Gupta
Yale New Haven Hospital
EG
Elizabeth L. Godfrey
Yale Cancer Center
KS
Kurt S. Schultz
Ver todo
Puntos clave
Patients with colorectal cancer peritoneal metastases showed better outcomes with HIPEC tailored to molecular subtypes.
In this study, treatment selection based on molecular subtypes improved therapeutic effectiveness, as indicated by response rates.
Assessment using molecular subtype classification highlighted significant variations in chemotherapy agent efficacy.
Tailored HIPEC approaches may enable more effective treatments, although further research is needed for broader applications.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases | Synapse
Cite This Study
Copy
Gupta et al. (Tue,) studied this question.
synapsesocial.com/papers/69a76058c6e9836116a2d007
https://doi.org/https://doi.org/10.1245/s10434-025-19057-z